MiR-22-silenced Cyclin A Expression in Colon and Liver Cancer Cells Is Regulated by Bile Acid Receptor

Transcriptome profiling and genome-wide DNA binding define the differential role of fenretinide and all-trans RA in regulating the death and survival of human hepatocellular carcinoma Huh7 cells

(2013) Ying Hu et al.   BIOCHEMICAL PHARMACOLOGY

The role of retinoic acid in hepatic lipid homeostasis defined by genomic binding and transcriptome profiling

(2013) Yuqi He et al.   BMC GENOMICS

MicroRNA-144 Regulates Hepatic ATP Binding Cassette Transporter A1 and Plasma High-Density Lipoprotein After Activation of the Nuclear Receptor Farnesoid X Receptor

(2013) Thomas Q. de Aguiar Vallim et al.   CIRCULATION RESEARCH

Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma

(2012) Hongying Su et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Farnesoid X Receptor Protects Hepatocytes From Injury by Repressing miR-199a-3p, Which Increases Levels of LKB1

(2012) Chan Gyu Lee et al.   GASTROENTEROLOGY

MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells

(2012) Silvia Alvarez-Díaz et al.   HUMAN MOLECULAR GENETICS

Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3

(2012) Bo Ling et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Hepatocarcinogenesis in FXR−/−Mice Mimics Human HCC Progression That Operates through HNF1α Regulation of FXR Expression

(2012) Nian Liu et al.   MOLECULAR ENDOCRINOLOGY

Function Annotation of Hepatic Retinoid x Receptor α Based on Genome-Wide DNA Binding and Transcriptome Profiling

(2012) Qi Zhan et al.   PLoS One

Tumor Suppressor miR-22 Determines p53-Dependent Cellular Fate through Post-transcriptional Regulation of p21

(2011) N. Tsuchiya et al.   CANCER RESEARCH

Increased Activation of the Wnt/ -Catenin Pathway in Spontaneous Hepatocellular Carcinoma Observed in Farnesoid X Receptor Knockout Mice

(2011) A. Wolfe et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells

(2011) Jian Li et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Roles of microRNA-29a in the Antifibrotic Effect of Farnesoid X Receptor in Hepatic Stellate Cells

(2011) J. Li et al.   MOLECULAR PHARMACOLOGY

MicroRNA-22 Regulates Hypoxia Signaling in Colon Cancer Cells

(2011) Munekazu Yamakuchi et al.   PLoS One

Bile acid toxicity structure–activity relationships: Correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A)

(2010) Ruchika Sharma et al.   BIOORGANIC & MEDICINAL CHEMISTRY

microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity

(2010) J Zhang et al.   BRITISH JOURNAL OF CANCER

An estrogen receptor α suppressor, microRNA-22, is downregulated in estrogen receptor α-positive human breast cancer cell lines and clinical samples

(2010) Jianhua Xiong et al.   FEBS Journal

A Pathway Involving Farnesoid X Receptor and Small Heterodimer Partner Positively Regulates Hepatic Sirtuin 1 Levels via MicroRNA-34a Inhibition

(2010) Jiyoung Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein

(2010) J Xiong et al.   ONCOGENE

Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine

(2009) Ann M. Thomas et al.   HEPATOLOGY

Bile acids: regulation of synthesis

(2009) John Y. L. Chiang   JOURNAL OF LIPID RESEARCH

Farnesoid X Receptor Deficiency in Mice Leads to Increased Intestinal Epithelial Cell Proliferation and Tumor Development

(2008) R. R.M. Maran et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS